Rilvegostomig is a bsAb targeting both TIGIT and PD-1 that demonstrated promising early signs of tolerability and efficacy in patients with advanced or metastatic PD-L1-positive NSCLC, following progression on at least one prior ICI (part A, B) according to initial findings from the phase 1/2 ARTEMIDE-01 study (NCT04995523) presented at the 2023 ASCO and 2023 ESMO annual meetings [117,118]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.